Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brett, M.
Right arrow Articles by Beatson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brett, M.
Right arrow Articles by Beatson, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 23-27, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis

M Brett, P Short and S Beatson
Institute of Environmental Science & Research Limited, Communicable Disease Centre, Porirua, New Zealand.

In spite of vaccination programmes, whooping cough epidemics continue to occur. The disease affects all age groups, although its severity is greatest in the young, with infants being particularly vulnerable. Erythromycin is generally accepted as the drug of choice both for treatment and for prophylaxis during epidemics. Roxithromycin is a macrolide with pharmacokinetic advantages over erythromycin; it is well absorbed, produces high serum concentrations, has a long half-life and penetrates respiratory secretions well. There are no accepted standards for testing the sensitivity of Bordetella pertussis to antibiotics, and reports of the activity of roxithromycin and erythromycin are variable. Using Isosensitest agar supplemented with 5% horse blood and an inoculum of 10(4) cfu, 88 strains of B. pertussis were tested for their sensitivity to roxithromycin, erythromycin, rifampicin and trimethoprim/sulphamethoxazole. The range of MICs was 0.12-0.5 mg/L for both roxithromycin and erythromycin. Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin). Since roxithromycin is well tolerated by children when used for respiratory tract infections, the good in-vitro activity against B. pertussis, combined with its favourable pharmacokinetics, suggest it may be a good candidate for use in the treatment and prophylaxis of whooping cough.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Microbiol. Mol. Biol. Rev.Home page
A. T. Bull, A. C. Ward, and M. Goodfellow
Search and Discovery Strategies for Biotechnology: the Paradigm Shift
Microbiol. Mol. Biol. Rev., September 1, 2000; 64(3): 573 - 606.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.